How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy
Max-Joseph Grimm
(1, 2)
,
Gesine Respondek
(1, 2)
,
Maria Stamelou
(3)
,
Thomas Arzberger
(2, 4)
,
Leslie Ferguson
(5)
,
Ellen Gelpi
(6, 7)
,
Armin Giese
(4)
,
Murray Grossman
(8)
,
David Irwin
(8)
,
Alexander Pantelyat
(9)
,
Alex Rajput
(5)
,
Sigrun Roeber
(4)
,
John van Swieten
(10)
,
Claire Troakes
(11)
,
Angelo Antonini
(12)
,
Kailash Bhatia
(13)
,
Carlo Colosimo
,
Thilo van Eimeren
(14)
,
Jan Kassubek
(15)
,
Johannes Levin
(16, 4)
,
Wassilios Meissner
(17, 18, 19, 20)
,
Christer Nilsson
(21)
,
Wolfgang Oertel
(22)
,
Ines Piot
(1, 2)
,
Werner Poewe
(23)
,
Gregor Wenning
(23)
,
Adam Boxer
(24)
,
Lawrence Golbe
(25)
,
Keith Josephs
(26)
,
Irene Litvan
(27)
,
Huw Morris
(28)
,
Jennifer Whitwell
(26)
,
Yaroslau Compta
(7)
,
Jean-Christophe Corvol
(29, 30)
,
Anthony Lang
(31)
,
James Rowe
(32)
,
Günter Höglinger
(1, 2)
1
TUM -
Technische Universität Munchen - Technical University Munich - Université Technique de Munich
2 DZNE - Deutsches Zentrum für Neurodegenerative Erkrankungen [Ulm]
3 “Attikon” University Hospital
4 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
5 U of S - University of Saskatchewan [Saskatoon, Canada]
6 Medizinische Universität Wien = Medical University of Vienna
7 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
8 University of Pennsylvania
9 JHU - Johns Hopkins University
10 Erasmus MC - Erasmus University Medical Center [Rotterdam]
11 King‘s College London
12 Unipd - Università degli Studi di Padova = University of Padua
13 UCL Queen Square Institute of Neurology
14 University of Cologne
15 Universitätsklinikum Ulm - University Hospital of Ulm
16 DZNE - German Research Center for Neurodegenerative Diseases - Deutsches Zentrum für Neurodegenerative Erkrankungen
17 IMN - Institut des Maladies Neurodégénératives [Bordeaux]
18 CHU Bordeaux
19 University of Otago [Dunedin, Nouvelle-Zélande]
20 NZBRI - New Zealand Brain Research Institute
21 Lund University
22 Philipps Universität Marburg = Philipps University of Marburg
23 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck
24 UC San Francisco - University of California [San Francisco]
25 NJMS - Rutgers New Jersey Medical School
26 Mayo Clinic [Rochester]
27 UC San Diego - University of California [San Diego]
28 Institute of Neurology [London]
29 ICM - Institut du Cerveau = Paris Brain Institute
30 CHU Pitié-Salpêtrière [AP-HP]
31 Toronto Western Hospital
32 CAM - University of Cambridge [UK]
2 DZNE - Deutsches Zentrum für Neurodegenerative Erkrankungen [Ulm]
3 “Attikon” University Hospital
4 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
5 U of S - University of Saskatchewan [Saskatoon, Canada]
6 Medizinische Universität Wien = Medical University of Vienna
7 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
8 University of Pennsylvania
9 JHU - Johns Hopkins University
10 Erasmus MC - Erasmus University Medical Center [Rotterdam]
11 King‘s College London
12 Unipd - Università degli Studi di Padova = University of Padua
13 UCL Queen Square Institute of Neurology
14 University of Cologne
15 Universitätsklinikum Ulm - University Hospital of Ulm
16 DZNE - German Research Center for Neurodegenerative Diseases - Deutsches Zentrum für Neurodegenerative Erkrankungen
17 IMN - Institut des Maladies Neurodégénératives [Bordeaux]
18 CHU Bordeaux
19 University of Otago [Dunedin, Nouvelle-Zélande]
20 NZBRI - New Zealand Brain Research Institute
21 Lund University
22 Philipps Universität Marburg = Philipps University of Marburg
23 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck
24 UC San Francisco - University of California [San Francisco]
25 NJMS - Rutgers New Jersey Medical School
26 Mayo Clinic [Rochester]
27 UC San Diego - University of California [San Diego]
28 Institute of Neurology [London]
29 ICM - Institut du Cerveau = Paris Brain Institute
30 CHU Pitié-Salpêtrière [AP-HP]
31 Toronto Western Hospital
32 CAM - University of Cambridge [UK]
David Irwin
- Fonction : Auteur
- PersonId : 1339577
- ORCID : 0000-0002-5599-5098
Angelo Antonini
- Fonction : Auteur
- PersonId : 1379079
- ORCID : 0000-0003-1040-2807
Carlo Colosimo
- Fonction : Auteur
Wassilios Meissner
- Fonction : Auteur
- PersonId : 758671
- ORCID : 0000-0003-2172-7527
- IdRef : 113664761
Anthony Lang
- Fonction : Auteur
- PersonId : 1163999
- ORCID : 0000-0003-1229-3667
- IdRef : 053496906
James Rowe
- Fonction : Auteur
- PersonId : 1343226
- ORCID : 0000-0001-7216-8679
Günter Höglinger
- Fonction : Auteur
- PersonId : 954906
- ORCID : 0000-0001-7587-6187
Résumé
Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them.
Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations.
Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1.
Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society.